Current Report ESPI 18/2025

The Management Board of Ryvu Therapeutics S.A. with its registered office in Krakow, Poland (“Company“) hereby informs that on June 12, 2025, the Company received two notifications prepared in accordance with Article 19.1 of MAR from AUGEBIT Fundusz Inwestycyjny Zamknięty managed by FORUM TFI S.A. with its registered office in Kraków, and from the Fundacja Rodziny Wesołowskich Fundacja Rodzinna w Krakowie, as persons closely associated with Mr. Tadeusz Wesołowski – Vice Chairman of the Supervisory Board of the Company.

As a result of the event described in the submitted notifications, the shareholding of Mr. Tadeusz Wesołowski in the Company, through persons closely associated with him, has not changed.

The content of the notifications is attached to this report.

Disclaimer: This English language translation has been prepared solely for the convenience of English-speaking readers. Despite all the efforts devoted to this translation, certain discrepancies, omissions or approximations may exist. In case of any differences between the Polish and the English versions, the Polish version shall prevail. Ryvu Therapeutics S.A., its representatives and employees decline all responsibility in this regard.

Legal basis: Art. 19.3 of MAR

 

Representatives of the Issuer:

• Paweł Przewięźlikowski – President of the Management Board
• Kamil Sitarz – Member of the Management Board